National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, ...

Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

TG Therapeutics' financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite ...

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...

Indirect comparisons suggest that the relapse rate with cladribine is similar to that of ocrelizumab and ofatumumab, the most commonly prescribed treatments for active RRMS. The CLARITY trial ...

Drug group or drug name Drug examples What can happen alemtuzumab (Campath, Lemtrada) — can increase the risk of immunosuppression as a side effect of Copaxone and alemtuzumab ocrelizumab ...